#USA #San Diego #Cancer Immunotherapy #Immorta Bio #SenoVax

Immorta Bio to Present at SITC Symposium

Immorta Bio Inc., a pioneering company specializing in longevity-focused biotechnologies, has announced its acceptance to present at the upcoming Society for Immunotherapy of Cancer (SITC) Spring Scientific, which will take place on March 12-13, 2025, in San Diego, California. This conference assembles the foremost experts in cancer immunotherapy, marking a pivotal occasion for Immorta Bio to share its novel scientific findings.

The focal point of Immorta Bio’s presentation will be its innovative senolytic immunotherapy, SenoVax. This cutting-edge product has shown promising preclinical results, particularly in combatting a variety of cancers, including glioma, lung, breast, and pancreatic cancers. The research elucidates the molecular and cellular mechanisms by which SenoVax selectively targets and eliminates senescent cells that contribute to cancer development and progression.

Dr. Thomas Ichim, the company's President and Chief Scientific Officer, emphasized the significance of this presentation, stating, "We plan to showcase data illustrating cancer regression in animal models affected by glioma, lung, breast, and pancreatic cancers through our SenoVax approach." Immorta Bio plans to initiate clinical trials for lung cancer soon, signaling potential advancements in cancer treatment methodologies.

Furthermore, the development of SenoVax is a result of fruitful collaborations with prestigious institutions, including the University of California San Diego, George Washington University, Cedars-Sinai, and Calidi Biosciences. This collaboration highlights the collective effort to advance cancer treatment through innovative research and technology.

Dr. Boris Reznik, the Chairman and CEO of Immorta Bio, expressed pride in the company's selection to present at such a reputable event. He remarked, "The Society for Immunotherapy of Cancer is the globally leading organization dedicated to the advancement of cancer immunotherapy. Being invited to present our findings signifies a noteworthy achievement for us and illustrates the acceptance of our paradigm-shifting approach where we address cancer by targeting senescent cells surrounding it."

The implications of SenoVax extend beyond cancer therapy. Based on preclinical data, Immorta Bio anticipates that the treatment could lead to a decrease in the systemic burden of senescent cells, potentially resulting in beneficial 'anti-aging' effects for patients receiving this therapy. This multifaceted approach to cancer care underscores the company's commitment to tackling age-related health challenges.

About Immorta Bio Inc.: Immorta Bio is recognized for its groundbreaking research on longevity, with a mission defined as "Treating Diseases of Aging and Treating Aging as Disease™." The company leverages advanced anti-aging technologies to address significant medical concerns, from severe cancers to various age-associated conditions. To learn more about Immorta Bio’s research initiatives and its pioneering health solutions, visit immortabio.com or engage with them via LinkedIn and Twitter.

Conclusion

The presentation at the SITC Symposium positions Immorta Bio at the forefront of cancer immunotherapy and longevity research. As its team prepares to present compelling data that could reshape current approaches to cancer treatment, the future looks promising for innovations that blend cancer therapy with anti-aging science.